Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma (ProApix)
Comparison of the Effects of Prophylactic Administration of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma and Patients Undergoing a Surgery for Total Knee Replacement
Patients with multiple myeloma (MM) are at high risk of venous thromboembolism (VTE) and these patients require adequate thromboprophylaxis. Following the publication of the AVERT clinical study, Apixaban is strongly recommended as a prophylactic treatment option for patients with cancer, based on high quality of evidence and a favorable efficacy/safety profile. A multicenter and ancillary study - APIXABOR - that measured the plasmatic concentration of Apixaban in patients with MM and treated with preventive dose has been conducted. The peak drug concentration was superior in MM plasma, as compared to non-myeloma patients under prophylaxis. Therefore, the present study evaluated whether differences in pharmacokinetics have an impact on pharmacodynamics (i.e. decrease in coagulability in MM patients as compared to non-MM patients undergoing a surgery for total knee replacement who also have VTE prophylaxis). In fine, this study may inform to better manage thromboprophylaxis in MM patients.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Emilie CHALAYER, MD
- Phone Number: 33 (0)477822814
- Email: emilie.chalayer@chu-st-etienne.fr
Study Contact Backup
- Name: Florence RANCON
- Phone Number: 33 (0)4 77 82 94 58
- Email: florence.rancon@chu-st-etienne.fr
Study Locations
-
-
-
Saint-Etienne, France, 42055
- Recruiting
- CHU de Saint-Etienne
-
Sub-Investigator:
- Julien LANOISELEE, MD
-
Sub-Investigator:
- Ludovic FOUILLET, MD
-
Sub-Investigator:
- Jean-Yves BIEN, MD
-
Sub-Investigator:
- Emmanuelle TAVERNIER, MD
-
Contact:
- Emilie CHALAYER, MD
- Phone Number: 33 (0)4 77 82 28 14
- Email: emilie.chalayer@chu-st-etienne.fr
-
Sub-Investigator:
- Jérôme CORNILLON, MD
-
Sub-Investigator:
- Charlotte DOUBLET, MD
-
Sub-Investigator:
- Tiphany NEEL, MD
-
Sub-Investigator:
- Manon SAPET, MD
-
Sub-Investigator:
- Hugo THEVENET, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old,
- Signed informed consent,
- Patient covered by a social security scheme.
- Group 1 : patient with a diagnosis of de novo multiple myeloma, with an indication of thromboprophylaxis with Apixaban,
- Group 2 : patient requiring a surgery for total knee replacement, , with an indication of thromboprophylaxis with Apixaban.
Exclusion Criteria:
- Curative doses of anticoagulation treatment,
- Contra-indication to Apixaban,
- Pregnant or breastfeeding woman,
- Refusal to sign consent,
- Patient under legal protection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Blood sampling of patients with de novo multiple myeloma
Description: Blood sampling of patients with de novo multiple myeloma |
Blood sampling Treatment by Apixaban |
|
Experimental: Blood sampling of patients undergoing total knee replacement
Description: Blood sampling of patients undergoing total knee replacement |
Blood sampling Treatment by Apixaban |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endogenous Thrombin potential (nM.min)
Time Frame: 2 hours after Apixaban Treatment
|
Endogenous Thrombin potential (nM.min) as measured with MidiCAT method at the concentration peak 2 hours after 2.5mg Apixaban treatment |
2 hours after Apixaban Treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Apixaban concentration (ng/mL)
Time Frame: Kinetics of 12 hours following Apixaban treatment in both groups
|
Apixaban concentration (ng/mL) as measured by mass spectrometry during 12 hours following Apixaban treatment (2.5mg) in both groups |
Kinetics of 12 hours following Apixaban treatment in both groups
|
|
Pharmacodynamics' kinetics of Endogenous Thrombin Potential
Time Frame: Kinetics of 12 hours following Apixaban treatment in both groups
|
MidiCAT method measure : Endogenous Thrombin Potential (nM.min) |
Kinetics of 12 hours following Apixaban treatment in both groups
|
|
Pharmacodynamics' kinetics of Lagtime
Time Frame: Kinetics of 12 hours following Apixaban treatment in both groups
|
MidiCAT method measure : Lagtime (min) |
Kinetics of 12 hours following Apixaban treatment in both groups
|
|
Pharmacodynamics' kinetics of Time to peak
Time Frame: Kinetics of 12 hours following Apixaban treatment in both groups
|
MidiCAT method measure : Time to peak (min) |
Kinetics of 12 hours following Apixaban treatment in both groups
|
|
Pharmacodynamics' kinetics of Thrombin peak
Time Frame: Kinetics of 12 hours following Apixaban treatment in both groups
|
MidiCAT method measure : Thrombin peak (M, Thrombin) |
Kinetics of 12 hours following Apixaban treatment in both groups
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Emilie CHALAYER, MD, CHU de Saint-Etienne
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Neoplasms, Plasma Cell
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Hemic and Lymphatic Diseases
- Multiple Myeloma
- Investigative Techniques
- Specimen Handling
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Punctures
- Surgical Procedures, Operative
- apixaban
- Blood Specimen Collection
Other Study ID Numbers
Other Study ID Numbers
- 23CH293
- 2024-515329-27-00 (Ctis)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.